Eli Lilly Offers Obesity Drug Directly to Consumers

In January 2024, Eli Lilly launched LillyDirect, a direct-to-patient portal that gives some patients access to the anti-obesity drug Zepbound for as little as $25 a month. Obesity rates continue to increase and finding effective medications can be a challenge, with shortages and high costs being common. Lilly’s new portal and other developments are promising. GLP-1 medications, like Zepbound, have shown cardiovascular health benefits in addition to weight loss. There has also been a push for insurance coverage of weight loss medications. While there are concerns about direct-to-patient portals, this new development signals a positive shift in how obesity medications can reach patients.

Source link

error: Content is protected !!